|Program||Target Indication||Region||Research||Preclinical||Phase I||Phase II||Phase III||Filing||Approval||Out-licensed|
|Chugai Pharmaceutical Co., Ltd.|
|Hematologic cancer||Developing in-house|
|Solid tumor||FUJIFILM Corporation|
PPMX-T001 targets glypican 3 (GPC3), which is expressed on the surface of cancer cells. A transcriptome analysis performed by LSBM at the University of Tokyo has revealed that GPC3 is highly expressed in liver cancer. GPC3 is an approximately 60-kDa glycoprotein associated with the cell membrane via a glycosylphosphatidylinositol anchor. Currently, PPMX-T001 with atezolizumab, which promotes reactivation of T-cells, is under evaluation for treating liver cancer in a clinical trial sponsored by Chugai Pharmaceutical Co., Ltd.
PPMX-T002 targets cadherin 3 (CDH3) that is expressed on the surface of cancer cells. A transcriptome analysis performed by LSBM at the University of Tokyo has revealed that CDH3 is highly expressed in various cancers but is poorly expressed in major healthy organs.
We licensed out to FUJIFILM Corporation a chimeric antibody against CDH3, generated by a hybridoma method. Clinical trials on this anti-cancer RI-labeled antibody that attacks cancer cells effectively while maintaining side effects at a low level have been ongoing in the USA and Japan against solid tumors by FUJIFILM group.
PPMX-T003 targets transferrin receptor (TfR) that is expressed on the cell membrane and regulates cellular iron uptake. The cellular iron uptake is essential for cell survival and proliferation. As TfR is highly expressed in many cancer cells, the inhibition of iron uptake depletes its levels within cells, leading to cell death. Using the phage display method, we have developed a fully human antibody, PPMX-T003, which kills cancer cells effectively with its extremely potent inhibitory activity against iron uptake. In late 2019, we started phase I clinical trial on PV, one of hematologic cancers in Japan.
PPMX-T004 targets CDH3. It is generated using the hybridoma method and has a high potency of internalization. It has been developed as an ADC (antibody drug conjugate) and is licensed to FUJIFILM Corporation. The target of PPMX-T004 is the same as that of PPMX-T002, however, the two drug candidates have different therapeutic fields due to use/non-use of RI.